Venue Analysis Following 1st Chinese Patent Office Rulings

The China National Intellectual Property Administration recently made two benchmark administrative rulings in a major patent infringement dispute. The case was brought by international innovator drug company Boehringer Ingelheim Pharma GmbH & Co. KG against two Chinese generic drug makers Guangdong HEC Pharmaceutical Co. Ltd. and Yichang HEC Changjiang Pharmaceutical Co. Ltd., and a series of injunctions were granted against the two generic drug makers.